Nervous System News and Research

Latest Nervous System News and Research

Study: Generic nifedipine product not bioequivalent to Adalat XL

An extended release generic nifedipine product (Mylan-Nifedipine extended release 60 mg formerly Gen-Nifedipine extended release 60mg, Genpharm ULC) is not bioequivalent to the Canadian originator product, Adalat(R) XL(R), according to the results of a study recently published in the International Journal of Clinical Pharmacology and Therapeutics.

4 Feb 2010

Study shows Cymbalta reduces chronic low back pain

In a new study, 60 mg of Cymbalta® (duloxetine HCl) taken once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) average pain rating, compared with placebo.

3 Feb 2010

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.

3 Feb 2010

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

California Stem Cell, Inc. (CSC) and ALS Therapy Development Institute (ALS TDI) are pleased to announce an extension and expansion of their collaboration aimed at advancing a potential stem cell therapy for ALS (amyotrophic lateral sclerosis). This effort will build on work that has already been completed as part of this on-going partnership to understand how stem cells, and their derivatives, may be applied to treatment of this fatal neurodegenerative disease.

3 Feb 2010

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on ALL

Treating acute lymphocytic leukemia (ALL) can bring many challenges, particularly in the adult population. To optimally manage this disease in adult patients, healthcare professionals must understand and identify characteristics of high-risk disease, utilize best strategies for preventing central nervous system relapse, and recognize the important role of post-remission hematopoietic stem cell transplantation in ALL therapy.

2 Feb 2010

Decreased release of neurotransmitter acetylcholine contributes to heart failure

Scientists at the Robarts Research Institute at The University of Western Ontario, working in collaboration with researchers in Brazil, have used a unique genetically-modified mouse line to reveal a previously unidentified mechanism contributing to heart failure.

2 Feb 2010

New therapeutic made from tobacco plants shown to arrest West Nile virus infection

A new therapeutic made from tobacco plants has been shown to arrest West Nile virus infection, according to a new study by Arizona State University scientist Qiang Chen and his colleagues.

2 Feb 2010

Decision Resources: Benlysta to garner more than $500M in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, following its expected regulatory approval in 2011 in the United States and Europe, Human Genome Sciences/GlaxoSmithKline's Benlysta will garner sales of more than $500 million in 2018 in the systemic lupus erythematosus drug market.

2 Feb 2010

Memory loss or decline in thinking abilities may indicate higher risk of stroke

People who experience memory loss or a decline in their thinking abilities may be at higher risk of stroke, regardless of whether they have been diagnosed with dementia, according to a new study published in the February 2, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

2 Feb 2010

FDA approves neurostimulation treatment for heart failure

The FDA recently approved the first study of neurostimulation as a treatment for heart failure, a chronic disease that affects nearly six million Americans and is the leading cause of hospitalization in America.

2 Feb 2010

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Romark Laboratories announced that it has initiated enrollment of patients in a clinical trial of Alinia® (nitazoxanide) for treating acute uncomplicated influenza including illness caused by the currently circulating H1N1 strain.

1 Feb 2010

Cephalon to acquire Swiss-based pharmaceutical company

Cephalon, Inc. (Nasdaq: CEPH) announced today that it has signed an agreement to acquire Mepha AG and its subsidiaries, a profitable, privately-held, Swiss-based pharmaceutical company.

1 Feb 2010

Interim positive data from Phase IIa clinical study of SYN115 for Parkinson’s disease

Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson’s disease.

1 Feb 2010

Tips to prevent potential health problems in the future

A new year, a new YOU! Some of the most popular resolutions include getting healthier. The Minnesota Chiropractic Association (MCA) encourages better health through lifestyle choices.

30 Jan 2010

New study identifies that SynDIG1 plays critical role in creating and sustaining synapses

A new study from UC Davis Health System identifies for the first time a brain protein called SynDIG1 that plays a critical role in creating and sustaining synapses, the complex chemical signaling system responsible for communication between neurons.

30 Jan 2010

Should medical workers participate in the development of "medicalized" weapons?

(Garrison, NY) The latest issue of the Hastings Center Report features articles on "medicalized" weapons that temporarily incapacitate targets, sharing the benefits of newly found biological resources, and applications of GINA (the Genetic Information Nondisclosure Act).

29 Jan 2010

NIDA supports Omeros' Addiction program

Omeros Corporation today announced that the National Institute on Drug Abuse (NIDA) is providing support for the Company's Addiction program. NIDA will fund substantially all of the costs of a Phase 2 clinical study to be conducted by New York State Psychiatric Institute researchers.

28 Jan 2010

Centering Healthcare Institute receives the Cares Award for its CenteringPregnancy Group Prenatal Care program

Centering Healthcare Institute has been honored by the Premier healthcare alliance with the 18th Annual Monroe E. Trout Premier Cares Award for its CenteringPregnancy Group Prenatal Care program, which provides an innovative prenatal group care model now present in more than 300 sites across America. Centering Healthcare Institute last night received the Cares Award and $70,000 for the work it has done to provide care to mothers and babies nationwide.

28 Jan 2010

Researchers to test newest implant in restoring vision damaged by disease

Researchers trying to restore vision damaged by disease have found promise in a tiny implant that sows seeds of new cells in the eye.

28 Jan 2010

ALS TDI and Oxford BioMedica extend collaboration to develop gene therapies for Lou Gehrig's disease

The ALS Therapy Development Institute and Oxford BioMedica announced today the extension of their collaboration following successful completion of the first phase. The extended collaboration, which is funded by the Muscular Dystrophy Association, aims to advance the development of Oxford BioMedica's preclinical gene therapy candidate, MoNuDin®, and to evaluate other gene-based strategies for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

28 Jan 2010

Nervous System News and Research

Latest Nervous System News and Research

Study: Generic nifedipine product not bioequivalent to Adalat XL

Study shows Cymbalta reduces chronic low back pain

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on ALL

Decreased release of neurotransmitter acetylcholine contributes to heart failure

New therapeutic made from tobacco plants shown to arrest West Nile virus infection

Decision Resources: Benlysta to garner more than $500M in 2018

Memory loss or decline in thinking abilities may indicate higher risk of stroke

FDA approves neurostimulation treatment for heart failure

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Cephalon to acquire Swiss-based pharmaceutical company

Interim positive data from Phase IIa clinical study of SYN115 for Parkinson’s disease

Tips to prevent potential health problems in the future

New study identifies that SynDIG1 plays critical role in creating and sustaining synapses

Should medical workers participate in the development of "medicalized" weapons?

NIDA supports Omeros' Addiction program

Centering Healthcare Institute receives the Cares Award for its CenteringPregnancy Group Prenatal Care program

Researchers to test newest implant in restoring vision damaged by disease

ALS TDI and Oxford BioMedica extend collaboration to develop gene therapies for Lou Gehrig's disease

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Nervous System News and Research

Latest Nervous System News and Research

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Newsletters you may be interested in